
Ostentus Therapeutics: A biotech firm innovating in cancer treatment with novel natural compounds.
Ostentus Therapeutics, founded with a mission to revolutionize cancer treatment, focuses on studying and developing novel natural compounds. The company's vision is to bring effective and innovative therapies to individuals affected by cancer. Their primary product, OST-01, is at the forefront of their research and development efforts, aiming to offer new hope in oncology. Ostentus Therapeutics targets the biotechnology and pharmaceutical markets, emphasizing cutting-edge cancer therapeutics.
Notable affiliates include a team of experienced management, directors, and advisors who guide the company's strategic direction. Key achievements include significant research milestones and publications in 2023 and 2024, showcasing their progress in cancer treatment innovation. Ostentus Therapeutics has made a substantial impact by advancing the understanding and application of natural compounds in oncology, positioning itself as a promising player in the biotech industry.

OnCusp Therapeutics
oncusptx.com

Starton Therapeutics

Terpenoid Therapeutics

Signet Therapeutics
Virsti Therapeutics

Grannus Therapeutics

LTZ Therapeutics

Kronos Bio

Outpost Medicine

OS Therapies
ostherapies.com

Oncternal Therapeutics
oncternal.com

Wave Therapeutics

Pheast Therapeutics
pheast.com

PanTher Therapeutics
panthertx.com

Scorpion Therapeutics
Companies similar to Ostentus Therapeutics include OnCusp Therapeutics, Starton Therapeutics, Terpenoid Therapeutics and Signet Therapeutics.
Ostentus Therapeutics was founded in 2021.
Ostentus Therapeutics' headquarters is located in Newport Coast, CA, US.
Ostentus Therapeutics' most recent funding round was for $1M (USD) in October 2022.
As of Oct 12, 2022, Ostentus Therapeutics has raised a total of $1.6M (USD).
Ostentus Therapeutics has 5 employees as of Feb 5, 2024.